公开(公告)号：EP3417062A1

公开(公告)日：2018-12-26

申请号：EP17753686.9

申请日：2017-02-13

申请人： Temple University - Of The Commonwealth System of Higher Education

发明人： KHALILI, Kamel ,  HU, Wenhui

IPC分类号： C12N15/11 ,  C12N15/113 ,  C12N9/22 ,  A61K48/00

CPC分类号： C12N9/22 ,  A01K2227/105 ,  A01K2267/0337 ,  A61K48/00 ,  C07K2319/09 ,  C12N15/1132 ,  C12N2310/20 ,  C12N2750/14143

摘要： Compositions for the in vivo delivery of a gene editing CRISPR/Cas9 complex was developed to eliminate integrated retroviral DNA sequences from latently infected human cells and animal disease models

公开(公告)号：EP2640186B1

公开(公告)日：2018-02-28

申请号：EP11791135.4

申请日：2011-11-15

申请人： Merial, Inc. ,  The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services

发明人： FISCHER, Laurent Bernard ,  KAMAHWI, Shaden ,  VALENZUELA, Jesus ,  SUAU, Hamide Aslan

IPC分类号： A01K67/027 ,  A61K39/008

CPC分类号： A01K67/027 ,  A01K2227/10 ,  A01K2267/0337 ,  A61K39/00 ,  Y02A50/41

摘要： The present invention provides a method for effectively and reproducibly infecting canines with Leishmania infantum using sand flies to vector the parasite. The inventive method comprises several steps, including ensuring canines are naïve to Leishmania, infecting the canines using bites of Leishmania-infected sand fly bites, and evaluating successful transmission of the Leishmania parasites.

公开(公告)号：EP2726499B1

公开(公告)日：2017-11-15

申请号：EP11868565.0

申请日：2011-07-25

申请人： Green Cross Corporation

发明人： KIM, Se-Ho ,  HONG, Kwang-Won ,  SHIN, Yong-Won ,  CHANG, Ki Hwan ,  KIM, Min-Soo ,  IM, Jung-Ae

IPC分类号： C07K14/02 ,  A61K39/29 ,  A61K39/42 ,  C07K16/08 ,  C12N15/36 ,  C07K17/02 ,  C12N15/63 ,  C12N7/01 ,  C12N15/85 ,  A61P31/20

CPC分类号： C07K14/005 ,  A01K67/027 ,  A01K2207/05 ,  A01K2227/105 ,  A01K2267/0337 ,  A61K39/00 ,  A61K39/292 ,  A61K2039/53 ,  C07K16/082 ,  C07K2317/34 ,  C07K2317/76 ,  C12N7/00 ,  C12N2730/10122 ,  C12N2730/10134 ,  C12N2730/10151

公开(公告)号：EP2486939B1

公开(公告)日：2017-07-12

申请号：EP12164331.6

申请日：2008-04-10

申请人： Oxford University Innovation Limited ,  GlaxoSmithKline Biologicals SA

发明人： Reyes, Arturo ,  Hill, Adrian ,  O'Hara, Geraldine ,  Colloca, Stefano ,  Cortese, Riccardo

IPC分类号： C12N15/86 ,  C07K14/445 ,  C07K16/20 ,  C07K14/78 ,  A61K39/015

CPC分类号： A61K39/015 ,  A01K2227/105 ,  A01K2267/0337 ,  A61K39/39 ,  A61K2039/5256 ,  A61K2039/545 ,  A61K2039/55561 ,  C07K14/445 ,  C07K14/78 ,  C07K16/205 ,  C12N15/86 ,  C12N2710/10334 ,  C12N2710/10343 ,  Y02A50/412 ,  Y10S435/975

摘要： The invention provides recombinant adenoviral vectors which are capable of eliciting immunity against the pre-erythrocytic stage of the life cycle of the malaria parasite. In particular, the invention provides a recombinant, replication deficient simian adenoviral vector which encodes an antigen comprising the thrombospondin-related adhesion protein (TRAP), and also immunogenic compositions (e.g. vaccines) comprising the vector and methods of using such compositions.

摘要翻译： 本发明提供了能够引发针对疟疾寄生虫的生命周期的红细胞前期阶段的免疫力的重组腺病毒载体。 具体而言，本发明提供了编码包含血小板反应蛋白相关粘附蛋白（TRAP）的抗原的重组复制缺陷型猿猴腺病毒载体，以及包含该载体的免疫原性组合物（例如疫苗）和使用该组合物的方法。

公开(公告)号：EP3056082A1

公开(公告)日：2016-08-17

申请号：EP16157878.6

申请日：2010-10-04

申请人： Regeneron Pharmaceuticals, Inc. ,  Yale University ,  Institute for Research in Biomedicine (IRB)

发明人： STEVENS, Sean ,  MURPHY, Andrew J. ,  FLAVELL, Richard ,  EYNON, Elizabeth ,  GALAN, Jorge ,  WILLINGER, Tim ,  MANZ, Markus, G. ,  RONGVAUX, Anthony ,  YANCOPOULOS, George D.

IPC分类号： A01K67/027 ,  C07K14/52 ,  C07K14/535 ,  C12N9/00 ,  C07K14/715 ,  C07K14/54 ,  A61K49/00

CPC分类号： A01K67/0278 ,  A01K67/0271 ,  A01K67/0275 ,  A01K2207/12 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0331 ,  A01K2267/0337 ,  A01K2267/0381 ,  A01K2267/0387 ,  A61K49/00 ,  C07K14/524 ,  C07K14/535 ,  C07K14/5403 ,  C07K14/7155 ,  C12N9/00

摘要： A mouse with a humanization of the mIL-3 gene and the mGM-CSF gene, a knockout of a mRAG gene, and a knockout of a mII2rg subunit gene; and optionally a humanization of the TPO gene is described. A RAG/II2rg KO/hTPO knock-in mouse is described. A mouse engrafted with human hematopoietic stem cells (HSCs) that maintains a human immune cell (HIC) population derived from the HSCs and that is infectable by a human pathogen, e.g., S. typhi or M. tuberculosis is described. A mouse that models a human pathogen infection that is poorly modeled in mice is described, e.g., a mouse that models a human mycobacterial infection, wherein the mouse develops one or more granulomas comprising human immune cells. A mouse that comprises a human hematopoietic malignancy that originates from an early human hematopoietic cells is described, e.g., a myeloid leukemia or a yeloproliferative neoplasia.

摘要翻译： 具有mIL-3基因和mGM-CSF基因的人源化的小鼠，mRAG基因的敲除和mII2rg亚基基因的敲除; 并且可选地描述了TPO基因的人源化。 描述了RAG / II2rg KO / hTPO敲入小鼠。 描述了维持人类免疫细胞（HIC）群体的人类造血干细胞（HSCs）的小鼠，所述人类免疫细胞（HIC）群体衍生自HSC并且可被人类病原体例如伤寒沙门氏菌或结核分枝杆菌感染。 描述了模拟在小鼠中模拟不良的人类病原体感染的小鼠，例如模拟人类分枝杆菌感染的小鼠，其中小鼠产生包含人免疫细胞的一种或多种肉芽肿。 描述了包含源于早期人类造血细胞的人类造血恶性肿瘤的小鼠，例如骨髓性白血病或叶绿体增生性肿瘤。

公开(公告)号：EP3004330A1

公开(公告)日：2016-04-13

申请号：EP14807294.5

申请日：2014-06-05

申请人： Agency for Science, Technology and Research

发明人： CHEN, Qingfeng ,  KENG, Choong Tat ,  TAN, Yee Joo ,  BERTOLETTI, Antonio

IPC分类号： C12N5/071 ,  C12N5/073 ,  C12N5/0735

CPC分类号： A01K67/0271 ,  A01K2207/12 ,  A01K2217/054 ,  A01K2227/105 ,  A01K2267/0337 ,  A61K49/0008 ,  C12N2770/24211

摘要： This invention refers to a mouse for human hepatitis studies wherein the mouse has been injected with CD34+ stem cells and wherein the mouse is immunocompromised, as well as a method of manufacturing a mouse model comprising administering CD34+ stem cells as defined herein into an immunocompromised mouse as defined herein. The invention also refers to the use of a mouse as defined for testing the efficiency of putative anti-HBV or anti-HCV drugs or for characterizing changes in viral quasispecies during HBV or HCV infection.

摘要翻译： 本发明涉及用于人肝炎研究的小鼠，其中小鼠已注射CD34 +干细胞并且其中小鼠免疫受损，以及制造小鼠模型的方法，该方法包括将如本文所定义的CD34 +干细胞施用至免疫受损小鼠中 在此定义。 本发明还涉及定义用于测试推定的抗-HBV或抗-HCV药物的效率或用于表征HBV或HCV感染期间病毒准种的变化的小鼠的用途。

公开(公告)号：EP2949208A1

公开(公告)日：2015-12-02

申请号：EP15166660.9

申请日：2010-05-26

申请人： Calimmune Inc.

发明人： Breton, Louis Randall ,  Chen, Irvin ,  An, Dong Sung ,  Symonds, Geoffrey P. ,  Boyd, Maureen ,  Millington, Michelle L.

IPC分类号： A01K67/027 ,  A61K35/28 ,  A61K48/00 ,  C07K14/00 ,  C07K14/16 ,  C07K14/47 ,  C12N9/90 ,  C12N15/85 ,  C12N15/867 ,  C12N15/113

CPC分类号： A61K35/28 ,  A01K67/0271 ,  A01K2207/12 ,  A01K2227/105 ,  A01K2267/0337 ,  A61K31/713 ,  A61K38/162 ,  A61K48/00 ,  A61K48/0058 ,  A61K2035/124 ,  C07K14/00 ,  C07K14/4702 ,  C07K2319/03 ,  C12N5/0647 ,  C12N7/00 ,  C12N9/90 ,  C12N15/1138 ,  C12N15/86 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/30 ,  C12N2320/31 ,  C12N2510/00 ,  C12N2740/16021 ,  C12N2740/16033 ,  C12N2740/16043 ,  C12N2740/16071 ,  C12N2740/16171 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2830/008 ,  C12N2830/85

摘要： The present invention provides an expression vector for preventing or inhibiting HlV entry, fusion or replication in mammalian cells. In particular, the invention provides a recombinant retroviral vector that encodes an inhibitor of a HlV co-receptor, such as CCR5 or CXCR4, and a protein that inhibits HIV fusion to target cells and/or HIV replication. Pharmaceutical compositions comprising such constructs and methods of use thereof to prevent or treat HIV infection in a patient are also disclosed.

摘要翻译： 本发明提供了用于在哺乳动物细胞中预防或抑制HlV进入，融合或复制的表达载体。 特别地，本发明提供了编码H1V共受体抑制剂如CCR5或CXCR4的重组逆转录病毒载体和抑制HIV融合靶向细胞和/或HIV复制的蛋白质。 还公开了包含这种构建体的药物组合物及其用于预防或治疗患者HIV感染的方法。

公开(公告)号：EP2453735B1

公开(公告)日：2015-07-08

申请号：EP10720980.1

申请日：2010-05-26

申请人： Calimmune Inc.

发明人： BRETON, Louis Randall ,  CHEN, Irvin ,  AN, Dong Sung ,  SYMONDS, Geoffrey P. ,  BOYD, Maureen ,  MILLINGTON, Michelle

IPC分类号： A01K67/027 ,  A61K35/28 ,  A61K48/00 ,  C07K14/00 ,  C07K14/16 ,  C07K14/47 ,  C12N9/90 ,  C12N15/85 ,  C12N15/867 ,  C12N15/113

CPC分类号： A61K35/28 ,  A01K67/0271 ,  A01K2207/12 ,  A01K2227/105 ,  A01K2267/0337 ,  A61K31/713 ,  A61K38/162 ,  A61K48/00 ,  A61K48/0058 ,  A61K2035/124 ,  C07K14/00 ,  C07K14/4702 ,  C07K2319/03 ,  C12N5/0647 ,  C12N7/00 ,  C12N9/90 ,  C12N15/1138 ,  C12N15/86 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/30 ,  C12N2320/31 ,  C12N2510/00 ,  C12N2740/16021 ,  C12N2740/16033 ,  C12N2740/16043 ,  C12N2740/16071 ,  C12N2740/16171 ,  C12N2740/16222 ,  C12N2740/16234 ,  C12N2830/008 ,  C12N2830/85

摘要： The present invention provides an expression vector for preventing or inhibiting HlV entry, fusion or replication in mammalian cells. In particular, the invention provides a recombinant retroviral vector that encodes an inhibitor of a HlV co-receptor, such as CCR5 or CXCR4, and a protein that inhibits HIV fusion to target cells and/or HIV replication. Pharmaceutical compositions comprising such constructs and methods of use thereof to prevent or treat HIV infection in a patient are also disclosed.

公开(公告)号：EP2865263A1

公开(公告)日：2015-04-29

申请号：EP14189856.9

申请日：2014-10-22

申请人： Wuhan Institute Of Virology Chinese Academy Of Sciences

发明人： Tang, Hong ,  Chen, Xin-Wen ,  Chen, Ji-Zheng ,  Zhao, Yang ,  Zhang, Chao ,  Chen, Hai-Rong

IPC分类号： A01K67/027

CPC分类号： A01K67/0275 ,  A01K67/02 ,  A01K67/0278 ,  A01K2217/052 ,  A01K2227/105 ,  A01K2267/0337

摘要： The present invention provides a CD81 and OCLN double transgenic mouse and its construction method and use. The double transgenic mouse can be used to constitute acute and chronic HCV infection in a mouse model.

摘要翻译： 本发明提供CD81和OCLN双转基因小鼠及其构建方法和用途。 双转基因小鼠可用于在小鼠模型中构成急性和慢性HCV感染。

公开(公告)号：EP2842417A1

公开(公告)日：2015-03-04

申请号：EP13780731.9

申请日：2013-04-25

申请人： Tokyo Metropolitan Institute of Medical Science ,  Chugai Seiyaku Kabushiki Kaisha ,  Phoenixbio Co., Ltd.

发明人： KOHARA, Michinori ,  JISHAGE, Koichi ,  KAWASE, Yosuke ,  MUKAIDANI, Chise ,  OSHITA, Hiroki ,  HAMAMURA, Satoko

IPC分类号： A01K67/027 ,  G01N33/15 ,  G01N33/50 ,  C12N15/09

CPC分类号： A01K67/0275 ,  A01K67/0271 ,  A01K2207/12 ,  A01K2207/15 ,  A01K2217/052 ,  A01K2217/15 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/0337 ,  A01K2267/035 ,  C12N9/6462 ,  C12N15/8509 ,  C12N15/8775 ,  C12N2015/8581 ,  G01N33/5067 ,  G01N33/5088 ,  Y10T436/146666

摘要： The present invention provides a mouse with liver damage, having a high degree of damage against the mouse's original hepatocytes while having a uPA gene in a heterozygous form, and a method for efficiently preparing the mouse. Specifically, the method for preparing a mouse with liver damage having the uPA gene in a heterozygous form comprises the following steps of:
(i) transforming mouse ES cells with a DNA fragment containing a liver-specific promoter/enhancer and cDNA that encodes a urokinase-type plasminogen activator operably linked under the control thereof;
(ii) injecting the transformed mouse ES cells obtained in step (i) into a host embryo;
(iii) transplanting the host embryo obtained in step (ii) via the injection of the ES cells into the uterus of a surrogate mother mouse, so as to obtain a chimeric mouse; and
(iv) crossing the chimeric mice obtained in step (iii), so as to obtain a transgenic mouse in which the DNA fragment is introduced in a heterozygous form.